The inclusion of IFN-α in the treatment protocol in Cuba could explain a low rate of patients complicated at serious stages of the disease (about 7% during the latest outbreak of COVID-19), as evidenced by public data (covid19cubadata.github.io/#cuba) and also, as compared to the 12% of SARS-CoV-2 positive patients who required ICU admission (140). This evidence concerns the gene IFNA2 and COVID-19.